

09/980824

JC10 rec'd PCT/PTO

Page 1 of 2

SERIAL NO.

7

DEC 2001

| | | | | |
|-----------------------------|--|--|--------------------------------------|------------------------------|
| Form PTO-1449 (MODIFIED) | U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE | | ATTY. DOCKET NO. 016915-0252 | SERIAL NO. Unassigned |
| | INFORMATION DISCLOSURE CITATION | | APPLICANT Gerd GEISSLINGER et al. | |
| | (Use several sheets if necessary) | | FILING DATE December 7, 2001 | GROUP ART UNIT Unassigned |
| | | | | |

U.S. PATENT DOCUMENTS

| EXAMINER INITIAL | REF | DOCUMENT NUMBER | DATE | NAME | CLASS | SUB-CLASS | FILING DATE IF APPROPRIATE |
|------------------|-----|-----------------|---------------|-------------------|-------|-----------|----------------------------|
| | A1 | 4,788,219 | Nov. 29, 1988 | Sakurai et al. | | | |
| | A2 | 5,057,304 | Oct. 15, 1991 | Eichelbaum et al. | | | |
| | A3 | 5,817,800 | Oct. 6, 1998 | Hoos et al. | | | |
| | | | | | | | |
| | | | | | | | |
| | | | | | | | |

FOREIGN PATENT DOCUMENTS

| | REF | DOCUMENT NUMBER | DATE | COUNTRY | CLASS | SUB-CLASS | TRANSLATION | |
|--|-----|-----------------|----------------|---------|-------|-----------|-------------|--|
| | | | | | | | YES | |
| | A4 | 0 595 133 | May 4, 1994 | EPO | | | | |
| | A5 | 0 647 450 | April 12, 1995 | EPO | | | | |
| | | | | | | | | |
| | | | | | | | | |
| | | | | | | | | |

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

| | | |
|--|----|---|
| | A6 | Desbene et al., "Application of the ADEPT Strategy to the MDR Resistance in Cancer Chemotherapy," Anti-Cancer Drug Design, Vol. 14, No. 2 (April 1999), pp. 93-106. |
| | A7 | Sperker et al., "Drug Targeting by Glucuronide Prodrugs: Regulation of the Bioactivating Enzyme Beta-Glucuronidase in the Hepatoma Cell Line HEPG2," Naunyn-Schmiedeberg's Archives of Pharmacology, Vol. 357, No. 4, Suppl., PP. R19, Meeting Info.: 39th Spring Meeting of the German Society for Experimental and Clinical Pharmacology and Toxicology, Mainz, Germany, March 17-19, 1998; German Society. |
| | A8 | Sperker et al., "The Role of Beta-Glucuronidase in Drug Disposition and Drug Targeting in Humans," Clinical Pharmacokinetics, Vol. 33, No. 1 (1997), pp. 18-31. <i>Draft copy</i> |
| | A9 | Bosslet et al., "Elucidation of the Mechanism Enabling Tumor Selective Prodrug-Monotherapy," Cancer Research, Vol. 58, No. 6 (March 15, 1998), pp. 1195-1201. <i>Draft copy</i> |

| | | |
|----------|--------------------|-----------------|
| EXAMINER | <i>[Signature]</i> | DATE CONSIDERED |
|----------|--------------------|-----------------|

6-3-03

* EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include any copy of this form with next communication to applicant.

| | | | | |
|--|-----|---|---------------------------------|--------------------------|
| Form PTO-1449 (MODIFIED) | | U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE | ATTY. DOCKET NO. 016915-0252 | SERIAL NO. 09/980,824 |
| INFORMATION DISCLOSURE CITATION <i>(Use several sheets if necessary)</i> | | APPLICANT Gerd GEISSLINGER et al. | | |
| | | FILING DATE 12/07/2001 | GROUP ART UNIT Unassigned | |
| OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.) | | | | |
| (5) | A13 | Sperker et al., "Inhibition of Escherichia Coli β -Glucuronidase by Verapamil: Effect on Enterohepatic Cycling of Morphine/Morphine-6-Glucuronide in Rats," European Journal of Clinical Pharmacology, p. 55 (1999). | | |
| (6) | A14 | Mickisch et al., "Dexverapamil to Modulate Vinblastine Resistance in Metastatic Renal Cell Carcinoma," Cancer Research Clinic of Oncology, Vol. 121, pp. R11-R16 (1995). | | |
| (6) | A15 | Volm, "Multidrug Resistance and its Reversal," Anticancer Research, Vol. 18, pp. 2905-2918 (1998). | | |
| (6) | A16 | Wainer, "Stereoisomers in Clinical Oncology: Why it is Important to Know What the Right and Left Hands are Doing," Annals of Oncology, Vol. 4, pp. S7-S13 (1993). | | |
| (6) | A17 | Simpson, "The Calcium Channel Blocker Verapamil and Cancer Chemotherapy," Cell Calcium, Vol. 6, pp. 449-467 (1985). | | |
| (6) | A18 | Ling, "Multidrug Resistance: Molecular Mechanisms and Clinical Relevance," Cancer Chemotherapy Pharmacology, Vol. 40, pp. S3-S8 (1997). | | |
| (6) | A19 | Aasmundstad et al., "Different Biotransformation of Morphine in Isolated Liver Cells from Guinea Pig and Rat," Biochemical Pharmacology, Vol. 46, No. 6, pp. 961-968 (1993). | | |
| (6) | A20 | Shah et al., "The Calcium Channel Antagonist, Verapamil, Potentiates the Inhibitory Action of Morphine on Intestinal and Biliary Motility," Journal of Pharmaceutical Pharmacology, Vol. 39, pp. 1037-1038 (pp. 1987). | | |
| (6) | A21 | Krevsky et al., "Effect of Verapamil on Human Intestinal Transit," Digestive Diseases and Sciences, Vol. 37, No. 6, pp. 919-924 (1992). | | |
| (6) | A22 | Schmidt et al., "Opioid Receptor Agonist Potencies of Morphine and Morphine-6-Glucuronide in the Guinea-Pig Ileum," European Journal of Pharmacology, Vol. 255, pp. 245-247 (1994). | | |
| (6) | A23 | Hartley et al., "Analysis of Morphine and its 3- and 6-Glucuronides by High Performance Liquid Chromatography with Fluorimetric Detection Following Solid Phase Extraction from Neonatal Plasma," Biomedical Chromatography, Vol. 7, pp. 34-37 (1993). | | |
| (6) | A24 | Lowry et al., "Protein Measurement with the Folin Phenol Reagent," Journal of Biological Chemistry, Vol. 193, pp. 265-275 (1951). | | |
| (6) | A25 | Sperker et al., "Interindividual Variability in Expression and Activity of Human β -Glucuronidase in Liver and Kidney: Consequences for Drug Metabolism," The Journal of Pharmacology and Experimental Therapeutics, Vol. 281, No. 2, pp. 914-920 (1997). | | |
| | | | | |
| | | | | |
| | | | | |

Bil

6-2-53

| | | | | | |
|--|--|--|--|---------------------------------|--------------------------|
| Form PTO-1449 (MODIFIED) | | U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE | | ATTY. DOCKET NO. 016915-0252 | SERIAL NO. 09/980,824 |
| INFORMATION DISCLOSURE CITATION (Use several sheets if necessary) | | APPLICANT | | Gerd GEISSLINGER et al. | |
| | | FILING DATE | | GROUP ART UNIT | |
| | | 12/07/2001 | | Unassigned | |

U.S. PATENT DOCUMENTS

| EXAMINER INITIAL | REF | DOCUMENT NUMBER | DATE | NAME | CLASS | SUB-CLASS | FILING DATE IF APPROPRIATE |
|------------------|-----|-----------------|---------------|----------------|-------|-----------|----------------------------|
| 3 | A1 | 5,447,719 | Sept. 5, 1995 | Kamataki | 424 | 195.1 | |
| Q | A2 | 5,817,800 | Oct. 6, 1998 | Bosslet et al. | 536 | 53 | |

FOREIGN PATENT DOCUMENTS

| | REF | DOCUMENT NUMBER | DATE | COUNTRY | CLASS | SUB-CLASS | TRANSLATION |
|---|-----|-----------------|--------------|---------|-------|-----------|-------------|
| | | | | | | | YES NO |
| G | A3 | 0 822 192 | Feb. 4, 1998 | EPO | 1 | 1 | Abstract |

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

| | | | | | | | |
|---|-----|--|--|--|--|--|--|
| G | A4 | Bernacki et al., "Glycosidases in Cancer and Invasion," Cancer and Metastasis Reviews, Vol. 4, pp. 81-101 (1985). | | | | | |
| | | Nakajima et al., "Heparanases and Tumor Metastasis," Journal of Cellular Biochemistry, Vol. 36, pp. 157-167 (1988). | | | | | |
| Q | A6 | Niwa et al., "A New Potent β -Glucuronidase Inhibitor, D-Glucaro- δ -lactam Derived from Nojirimycin," Journal of Biochemistry, Vol. 72, pp. 207-211 (1972). | | | | | |
| | | Takasuna et al., "Protective Effects of Kampo Medicines and Baicalin against Intestinal Toxicity of a New Anticancer Camptothecin Derivative, Irinotecan Hydrochloride (CPT-11), in Rats," Japanese Journal of Cancer Research, Vol. 86, pp. 978-984 (1995). | | | | | |
| G | A8 | Sperker et al., "The Role of β -Glucuronidase in Drug Disposition and Drug Targeting in Humans," Clinical Pharmacokinetics, Vol. 33, No. 1, pp. 18-31 (1997). | | | | | |
| | | Bosslet et al., "Fusion Protein Mediated Prodrug Activation (FMPA) In Vivo," Cell Biophysics, Vols. 24-25 (1994). | | | | | |
| G | A10 | Bosslet et al., "Tumor-selective Prodrug Activation by Fusion Protein-mediated Catalysis," Cancer Research, Vol. 54, pp. 2151-2159 (1994). | | | | | |
| | | Bosslet et al., "Elucidation of the Mechanism Enabling Tumor Selective Prodrug Monotherapy," Cancer Research, Vol. 58, pp. 1195-1201 (1998). | | | | | |
| G | A12 | Murdter et al., "Enhanced Uptake of Doxorubicin into Bronchial Carcinoma: β -Glucuronidase Mediates Release of Doxorubicin from a Glucuronide Prodrug (HMR 1826) at the Tumor Site," Cancer Research, Vol. 57, pp. 2440-2445 (1997). | | | | | |

| | | |
|----------|--------------|-----------------|
| EXAMINER | <i>Britt</i> | DATE CONSIDERED |
|----------|--------------|-----------------|

6-2-03

* EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include any copy of this form with next communication to applicant.